In the AD line, Donanemab announced phase 3 clinical results and re-submitted BLA, other notable developments include the next generation BTK inhibitor Pirtobrutinib results from phase 1/phase 2 CLL trials, IL23p19 monoclonal antibody Mirikizumab's approval in Europe, and PD-1 monoclonal antibody Peresolimab's first-time results of RA indication
The immune system is encountering a new peptide
I was thinking more clearly
1 source of news for every West Australian No lock-in contract Digital $8 $4 Save $32
The prevalence rates vary across different conditions: Rheumatoid Arthritis: 4.9% to 6.6% 5-7 Spondyloarthritis: 11.1% to 12.6% 5-7 Connective tissue diseases such as Sjgren's Syndrome and Systemic Lupus Erythematosus: 11.3% to 13.4% 5-7 The American College of Rheumatology (ACR) guidelines established for diagnosing fibromyalgia changed over time: 1990 Criteria: Focused on widespread pain and tender points, which are sensitive areas of the body that cause pain when pressed
This mechanism enhances fat metabolism and supports body composition improvement without affecting blood glucose, insulin sensitivity, or IGF-1 levels like full-length growth hormone would
